科州药物控制权稳定性遭问询：美籍董事长控股24%，多名股东存在关联关系

Core Viewpoint - Keshou Pharmaceutical Co., Ltd. is preparing for an IPO on the Beijing Stock Exchange, focusing on innovative small molecule drugs for cancer treatment, with a significant emphasis on the MAPK signaling pathway [2] Group 1: Company Overview - Keshou Pharmaceutical was established in 2014 and specializes in the research and development of innovative drugs for cancer treatment, having entered the commercialization phase [2] - The company's research pipeline includes important indications such as melanoma, non-small cell lung cancer, colorectal cancer, neurofibromatosis type 1, and radiotherapy protection [2] Group 2: Financial Performance - The projected operating revenues for Keshou Pharmaceutical from 2022 to the first half of 2025 are as follows: 3.42 million, 2.25 million, 17.48 million, and 22.87 million yuan respectively [2] - The net losses for the same periods are projected to be 125 million, 71.4 million, 110 million, and 182 million yuan respectively [2] Group 3: Shareholding Structure - HONGQI TIAN directly holds 17.05% of the company's shares and is the controlling shareholder, with an additional 6.72% held through Shanghai Changxue, totaling 23.77% [2] - The company's shareholding is relatively dispersed, with Decheng Ke Chow holding over 10% and connections among several shareholders [3] Group 4: Regulatory Requirements - The Beijing Stock Exchange has requested Keshou Pharmaceutical to clarify the basis for identifying the actual controller, considering the company's articles of association, shareholder meeting attendance, and management background [5] - The company is also required to explain the implications of a low shareholding percentage of the actual controller on control stability and governance effectiveness [5]